Physician profile
A Joel Papowitz
NPI 1477675098
$880.70
in general payments reported to CMS, 2019-2025
10 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.43 · 2020: $14.16 · 2022: $21.84 · 2023: $115 · 2024: $184 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623 · Consulting Fee: $150 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.28 |
| Consulting Fee | $150.00 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $224.69 | 2023-2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $207.05 | 2024-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $167.56 | 2023-2025 | Lumryz |
| Inspire Medical Systems, INC. | $91.56 | 2023-2024 | Inspire |
| Harmony Biosciences LLC | $74.70 | 2024 | |
| Merck Sharp & Dohme LLC | $53.83 | 2022-2023 | Belsomra |
| Optinose US, INC. | $16.71 | 2025 | |
| Medline Industries Lp | $16.43 | 2019 | |
| Organogenesis INC. | $14.16 | 2020 | |
| Lilly USA, LLC | $14.01 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw A Joel Papowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.